Patients with early-stage Parkinson’s disease could benefit from an innovative treatment that was launched in the UK in April.
The transdermal delivery system of Neupro provides consistent and continuous drug delivery over 24 hours. The patient needs to wear a patch, which is applied once a day. Drug delivery via a transdermal patch eliminates the peaks and troughs in drug levels associated with oral treatment that can lead to fluctuations in symptom control.
“This treatment has the potential to overcome many of the problems associated with oral administration and may well prove to be one of the most effective methods of delivering a steady and continuous dose,” stated Dr K Ray Chaudhuri, consultant neurologist, University Hospital Lewisham.
